Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Differentiated Thyroid Cancer

Differentiated Thyroid Cancer Clinical Trial

— Gisel  

Official title:

Observational Study on Gender-based Impact on Safety and Efficacy of Lenvatinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05789667
• Other study ID #: RS1316/20(2312)
• Status: Recruiting
• Start date: May 27, 2020
• Est. completion date: December 31, 2024

Study information

• Verified date: April 2024
• Source: Regina Elena Cancer Institute
• Contact: Marialuisa Appetecchia, Prof
• Phone: 00390652666026
• Email: marialuisa.appetecchia[@]ifo.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Lenvatinib is approved for the treatment of radioiodine refractory differentiated thyroid cancer. Despite gender can play a crucial role un in safety and efficacy of oncological product, little is know on gender difference in lenvatinb effacacy and safety in the context of radioiodine refractory differentiated thyroid cancer.

The primary objective of the study is to assess safety and toxicity profile in male and female patients in terms of dose reduction. The secondary objectives are to assess sex and gender difference in: the number and the incidence of adverse events; response rate according to RECIST criteria 1.1; progression free survival, overall survival and duration of response.

Description:

Lenvatinib is an orally available potent inhibitor of the split-kinase family of transmembrane growth factor receptors including Flt-1/VEGFR-1 and KDR/VEGFR. Lenvatinib has been investigated in hepatocellular carcinoma and in RAI-resistant thyroid cancer (Phase III trials) and in other malignancies, showing high rates of activity. In RAI-resistant thyroid cancer, lenvatinib showed a remarkable response rate over placebo (65% vs 2), combined with a prolonged progression free survival (18.3 vs 3.6 months). It has been approved for the treatment of locally recurrent or metastatic, progressive RAI resistance-DTC in the United States, Europe, and Japan, based on the results from SELECT trial. Moreover, lenvatinib demonstrated a meaningful clinical activity (response rate 64.8% in treatment arm vs 1.5% in placebo arm, p<0.001;) significantly reducing the tumour burden, with a median maximum percentage change in tumour size of -42.9%. Response was mostly pronounced at the first assessment (median -24.7% at 8 weeks after randomization) but it has been observed even in the following months (-1.3% per month). Recently, the efficacy of lenvatinib was confirmed in specific patient population, such as elderly. Although the efficacy is remarkable toxic effects are considerable and not all patients have the same risk to benefit ratio from lenvatinib treatment. Results derived from controlled clinical trials are rarely replicable in the real-life because these trials are usually conducted in selected populations, in a highly controlled setting, optimized to show the effect of the drug.

In this context growing evidences are showing gender associated functions playing a role in cancer incidence, progression and response to therapy; gender disparities in toxicities and effectiveness of certain drugs used in the treatment of the most common cancer is already well known.The aim of the present study is to evaluate the safety and efficacy profile of Lenvatinib based on gender in patients with refractory iodine DTC.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: December 31, 2024
• Est. primary completion date: July 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with refractory iodine DTC treated with lenvatinib

• Signed written informed consent

Exclusion Criteria:

• Age < 18 years

Related Conditions & MeSH terms

• Differentiated Thyroid Cancer
• Gender
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Drug:
• Lenvatinib
Patients will be treated by lenvatinib as recommended by good clinical practice

Locations

Country	Name	City	State
Italy	Regina Elena National Cancer Institute	Rome

Sponsors (8)

Lead Sponsor	Collaborator
Regina Elena Cancer Institute	Istituto Auxologico Italiano, Istituto Oncologico Veneto IRCCS, University of Catania, University of Pisa, University of Roma La Sapienza, University of Siena, University of Turin, Italy

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Gender difference in Safety profile of lenvatinib treatment	Difference in lenvatinib dose reduction between male and female patients	1 year
Secondary	Gender difference in lenvatinib side effects incidence	Difference in number of lenvatinib side effects between male and female patients according to CTCAE 5.0	1 year
Secondary	Gender difference in lenvatinib response rate	Difference in lenvatinib response rate (CR+PR) according to RECIST response evaluation criteria 1.1 in male and female patients.	1 year
Secondary	Gender difference progression free survival and overall survival of patients treated with lenvatinib	Difference in progression free survival and overall survival of patients treated with lenvatinib in male and female patients.	1 year